BioMarin (BMRN) announced positive new data from studies of Voxzogo in children with achondroplasia and in ongoing clinical trials ...

Eli Lilly LLY and partner Incyte INCY announced that a late-stage study evaluating oral baricitinib in adolescent patients ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

BioMarin Pharmaceutical (Nasdaq: BMRN) reported $747.31 million in revenue for the fourth quarter, a 16% year-over-year increase. The San Rafael-based global producer of genetic treatments for ...

The commercial failure of Biomarin and Behring’s AAV gene therapy programmes is surprising to many, considering positive clinical trial feedback. Credit: Marietjie via Shutterstock. Pfizer has ended ...

BioMarin Pharmaceutical has a twelve month low of $60.63 and a twelve month high of $94.85. The stock has a market cap of $13.56 billion, a price-to-earnings ratio of 32.35, a P/E/G ratio of 0.61 ...

BioMarin's enzyme replacement therapy (ERT) business, particularly Naglazyme and Palynziq, has shown strong growth. The enzyme business grew by 12% year-over-year in 2024, with Palynziq growing by 17% ...

BioMarin Pharmaceutical Inc. (NASDAQ ... with Palynziq growing by 17% due to increased penetration in the US and Japan. Analysts believe that the ERT business could contribute to exceeding mid ...

As Japan sees record-breaking numbers of foreign visitors, regional cities — in addition to major tourist destinations — are grappling with an unexpected surge in travelers. Social media has ...